<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/24/3260948/0/en/Press-Release-Sanofi-and-Regeneron-s-Dupixent-approved-in-Japan-as-the-first-targeted-medicine-to-treat-adults-with-bullous-pemphigoid.html">Press Release: Sanofi and Regeneron&#39;s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi and Regeneron&#39;s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Regeneron-Pharmaceuticals-US75886F1075">Regeneron Pharmaceuticals</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/03/24/3260952/0/en/Dupixent-dupilumab-Approved-in-Japan-as-the-First-Targeted-Medicine-to-Treat-Adults-with-Bullous-Pemphigoid-BP.html">Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)</a>
    </div>

      <div class="me-0 me-md-5">
        Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Regeneron-Pharmaceuticals-US75886F1075/load_more?page=9">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>